This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Prevention of vertical transmission of HIV

Authoring team

Vertical transmission can be reduced if HIV is detected before or during pregnancy.

The risk of transmission of HIV from mother to newborn is around 20% which can be reduced to less than 1% with appropriate interventions (1). Interventions used in preventing vertical transmission are:

 

  • giving antiretroviral therapy during
    • pregnancy
    • delivery and a short course for the baby
  • elective cesarean section (although in women with very low viral loads this intervention could be questionable)
  • avoiding breast feeding (1)

Zidovudine treatment reduces this risk to 8%. The regimen consists of:

  • oral zidovudine during pregnancy
  • intravenous zidovudine during labour
  • oral zidovudine for the infant for six weeks

A trial by Lallement et al. suggests that prolonged zidovudine therapy of the infant may not have additional benefit if the mother has received a long regimen of zidovudine during pregnancy. Conversely if the antenatal treatment period is shortened, the six week course for the infant is likely to be beneficial.

In countries with adequate resources combination drugs are now widely used.

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.